Literature DB >> 35597797

Transient alteration of consciousness in spinal cord injury secondary to Baclofen use: a case report.

Thomas John Pisano1, Jessica Ace2, Beverly Hon3,4.   

Abstract

INTRODUCTION: Oral baclofen is commonly used for spasticity management, especially with neurogenic bladder in spinal cord injury (SCI). A less common side effect of baclofen is transient alterations of consciousness, which can easily be confused for altered mental status secondary to orthostatic hypotension in SCI. CASE
PRESENTATION: A 43-year-old man with an acute SCI secondary to an aortic dissection was found to have episodes of confusion after titrating oral baclofen from 5 mg three times per day to 10 mg three times per day at an acute rehabilitation facility. Orthostatic hypotension was initially suspected as the cause of transient alterations of consciousness; however, he was never found to be hypotensive during these episodes. His confusion resolved several days after discontinuation of baclofen. DISCUSSION: Although, confusion and lightheadedness in SCI are commonly caused by orthostatic hypotension, it is important for physicians to be cognizant of baclofen's side effects, which increase in the setting of acute kidney injury (AKI). If an adverse effect is suspected, baclofen should be tapered while remaining observant for signs of baclofen withdrawal, which can be life-threatening. This case report is a reminder for clinicians to be aware of the uncommon adverse effects of baclofen when initiating therapy in SCI, especially in patients with AKI and neurogenic bladders.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35597797      PMCID: PMC9124195          DOI: 10.1038/s41394-022-00511-z

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  31 in total

Review 1.  Management of acute overdose or withdrawal state in intrathecal baclofen therapy.

Authors:  S V Watve; M Sivan; W A Raza; F F Jamil
Journal:  Spinal Cord       Date:  2011-10-18       Impact factor: 2.772

2.  Flumazenil counteracts intrathecal baclofen-induced central nervous system depression in tetanus.

Authors:  J M Saissy; M Vitris; J Demazière; M Seck; L Marcoux; M Gaye
Journal:  Anesthesiology       Date:  1992-06       Impact factor: 7.892

Review 3.  Reduced level of consciousness from baclofen in people with low kidney function.

Authors:  W Su; C Yegappan; E J F Carlisle; C M Clase
Journal:  BMJ       Date:  2009-12-31

4.  Dantrolene treatment for abrupt intrathecal baclofen withdrawal.

Authors:  A Khorasani; W T Peruzzi
Journal:  Anesth Analg       Date:  1995-05       Impact factor: 5.108

5.  A nationwide register-based survey of baclofen toxicity.

Authors:  Louise Bendix Kiel; Lotte Christine Groth Hoegberg; Tejs Jansen; John Asger Petersen; Kim Peder Dalhoff
Journal:  Basic Clin Pharmacol Toxicol       Date:  2014-11-22       Impact factor: 4.080

6.  Prolonged severe withdrawal symptoms after acute-on-chronic baclofen overdose.

Authors:  C T Peng; J Ger; C C Yang; W J Tsai; J F Deng; M J Bullard
Journal:  J Toxicol Clin Toxicol       Date:  1998

Review 7.  Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.

Authors:  J M Gracies; P Nance; E Elovic; J McGuire; D M Simpson
Journal:  Muscle Nerve Suppl       Date:  1997

8.  Baclofen Toxicity in Kidney Disease.

Authors:  Erin Wolf; Niraj R Kothari; John K Roberts; Matthew A Sparks
Journal:  Am J Kidney Dis       Date:  2017-09-09       Impact factor: 8.860

9.  Plasma and urinary excretion kinetics of oral baclofen in healthy subjects.

Authors:  E W Wuis; M J Dirks; E F Termond; T B Vree; E Van der Kleijn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 10.  Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder.

Authors:  Nicolas Simon; Nicolas Franchitto; Benjamin Rolland
Journal:  Front Psychiatry       Date:  2018-10-05       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.